Streetwise Reports' Article Archives — August 2023 back to current month (13)
Grey Wolf Animal Health Corp. has announced the financial results of the last quarter. Read on to see why one newsletter writer believes this stock is worth looking into.
Catalyst Rich 12 Months Ahead for U.S. Biopharma Co. (08/29/2023)
Investors can expect to see new drug application filings, a PDUFA meeting outcome, clinical trial results and revenue stream additions, noted a ROTH Capital Partners report.
This company has announced the general availability of its Linea IVT platform evaluation kits and the first kit shipment to an existing Linea IVT Template customer. It has also filed two provisional patent applications for its technologies to reduce the impurities and decrease manufacturing costs for mRNA therapies like some COVID-19 vaccines. Read to see what experts are saying about the stock.
FDA Approves New Oncology Drug for Clinical Trials (08/28/2023)
The first in-human trial of this investigative small molecule is expected to start in Q4/23, noted a Wedbush report.
Reliq Health Technologies Inc. has launched a new post-discharge program for acute care hospitals on its iUGO platform and signed contracts in California, Florida, and Puerto Rico.
Co. Still Undervalued Post Solid Q2/23 (08/16/2023)
The multistate operator is on a growth trend and just raised its free cash flow guidance for the year, noted a ROTH Capital Partners report.
Med Tech Firm's Q2/23 Revenue Beats Target (08/10/2023)
The company is expected to gain greater market share in one segment of its business, warranting a price target increase, noted a ROTH Capital Partners report.
Telehealth company Reliq Health Technologies signs contracts with 20 new rural health clinics (RHCs) in California, Nevada, Puerto Rico, Texas, and the U.S. Virgin Islands.
The long end of the bond market is starting to price in sticky inflation, and Ron Struthers of Struthers' Stock Reports expects interest rates to rise further. Higher energy prices will start adding to inflation again, adding to the problem. Moderna has broken down on the chart and will be reporting red ink in the next few years. Time to go short.
Biotech Co. An Attractive Investment (08/04/2023)
Technical Analyst Clive Maund reviews Awakn Life Sciences Corp.'s 26-month and year-to-date charts to tell you why he believes it is an attractive investment.
Telehealth Co. Continues To See Soaring Revenues (08/02/2023)
This telemedicine company just had its first profitable quarter, and now it could see revenues double twice over two fiscal years.
Co. Works to Strengthen Itself After Merger Ended (08/02/2023)
Its efforts include restructuring debt and divesting assets, noted a ROTH Capital Partners report.
Merger Between Two Firms Called Off (08/02/2023)
The deal broke down because the parties could not sell assets that had to be divested for it to go through, noted a ROTH Capital Partners report.